PROVIDENCE, Rhode Island, USA, June 2, 2026
Signati Medical has achieved a significant regulatory milestone after receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE) approval for a pivotal clinical study evaluating its Separo™ Vessel Sealing System, an innovative medical device designed to modernize and standardize vasectomy procedures. The approval enables the company to begin a randomized, controlled, multi-center clinical trial comparing the Separo™ System against mucosal cautery vasectomy, the current standard of care. The milestone marks an important step forward in the development of next-generation men’s health technologies aimed at improving procedural consistency, efficiency, and patient confidence in permanent contraception options. As healthcare systems continue to seek innovative solutions that expand access to family planning services, Signati Medical’s technology could help address long-standing gaps in male reproductive healthcare.
FDA Authorizes Pivotal Multi-Center Clinical Trial
The FDA IDE approval authorizes Signati Medical to conduct a randomized, controlled, open-label, non-inferiority clinical investigation across up to five U.S. medical institutions. The study will enroll 120 adult male participants and directly compare outcomes achieved with the Separo™ Vessel Sealing System against traditional mucosal cautery vasectomy procedures. Researchers will evaluate the device’s effectiveness using the accepted clinical standard for confirming sterility following vasectomy: the achievement of azoospermia or rare non-motile sperm levels during post-vasectomy semen analysis within six months of treatment.
The trial design reflects the rigorous evidence standards increasingly required by regulators, healthcare providers, and payers before adopting new medical technologies. By generating high-quality comparative clinical data, the study aims to establish whether the Separo™ System can deliver outcomes comparable to or better than current surgical techniques while potentially improving procedural consistency.
Addressing an Unmet Need in Men’s Reproductive Health
Advertisement
Although vasectomy remains one of the most effective and cost-efficient forms of permanent contraception, adoption rates continue to lag behind female sterilization procedures in the United States. Industry experts attribute this disparity to several factors, including limited patient awareness, provider variability, and the lack of purpose-built technologies designed specifically for vasectomy procedures.
Signati Medical was founded on the principle that family planning should be a shared responsibility, and that men should have access to advanced healthcare solutions that enable active participation in reproductive decision-making. The Separo™ Vessel Sealing System was specifically engineered to provide physicians with an energy-based vessel sealing platform optimized for vasectomy, helping reduce procedural variability while potentially improving efficiency and reproducibility. Company leadership believes that standardizing key aspects of the procedure may help improve patient confidence and broaden access to permanent male contraception options.
Building Evidence for Future Clinical Adoption
Beyond regulatory clearance, Signati Medical has designed the pivotal trial with broader healthcare adoption objectives in mind. The study’s randomized controlled design, multi-center execution, and objective clinical endpoints are intended to generate the level of evidence typically required by professional societies, guideline committees, and insurance payers when evaluating new medical technologies. Successful study outcomes could support future inclusion of the Separo™ System in clinical practice recommendations and reimbursement frameworks, helping accelerate physician adoption and patient access.
As healthcare providers increasingly seek technologies that improve procedural standardization and outcomes, the Separo™ Vessel Sealing System represents a novel approach to modernizing one of the most common urological procedures performed worldwide. The FDA IDE approval therefore represents not only a regulatory achievement for Signati Medical but also a potentially important advancement in the evolution of men’s health and reproductive medical device innovation.
Source: Signati Medical press release
